Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 129

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 129
---
|:----|:--|:------|:----|:--|
| Public offering price            | ​ | $                         |     | ​ | $               |     | ​ | $     |     | ​ |
| Placement Agent fees             | ​ | ​                         |     | ​ | ​               |     | ​ | ​     |     | ​ |
| Proceeds, before expenses, to us | ​ | $                         |     | ​ | $               |     | ​ | $     |     | ​ |

Indemnification We have agreed to indemnify Dawson James against certain liabilities, including liabilities under the Securities Act and liabilities arising from breaches of representations, warranties and covenants contained in our engagement letter with Dawson James. Determination of Public Offering Price and Warrant Exercise Price Our common stock is currently traded on The Nasdaq Capital Market under the symbol “PTPI.” On February 13, 2025, the closing price of our common stock was $0.2475 per share.

73

The final public offering price of the Units and the exercise price of the Series Warrants that we are offering, will be negotiated between us, Dawson James and the investors in this offering. We believe that the market price of our common stock at the date of this prospectus is not the appropriate public offering price for the shares of our common stock because the market price is affected by a number of factors. The principal factors considered by us and Dawson James in determining the final public offering price of the Units we are offering, as well as the exercise price of the Series Warrants that we are offering, included:

| ● | the recent trading history of our common stock on The Nasdaq Capital Market, including market prices and trading volume of our common stock; |

| ● | the current market price of our common stock on The Nasdaq Capital Market; |

| ● | the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; |

| ● | the information set forth in this prospectus and otherwise available to Dawson James; |

| ● | our past and present financial performance and an assessment of our management; |

| ● | our prospects for future earnings and the present state of our products; |

| ● | the current status of competitive products and product developments by our competitors; |

| ● | our history and prospects, and the history and prospects of the industry in which we compete; |

| ● | the general condition of the securities markets at the time of this offering; and |